Safety of Enfortumab Vedotin Plus Pembrolizumab in Hemodialysis Patients With Metastatic Urothelial Carcinoma: Case Report
A standard dose of EVP can be safely administered to patients on hemodialysis, with manageable toxicities comparable to those observed in nonhemodialysis patients. Although its antitumor efficacy was not confirmed, our experience suggests that EVP may remain a therapeutic option for selected dialysis patients with mUC.
Authors
- Toshio Takagi (ORCID: https://orcid.org/0000-0003-1775-0943)
- Kazutaka G. Nakamura (ORCID: https://orcid.org/0000-0002-1934-911X)
- Yuki Kobari (ORCID: https://orcid.org/0000-0002-1407-2588)
- Toshihisa Mizuno (ORCID: https://orcid.org/0000-0002-6878-5911)
- Hideki Ishida
- Kazuhiko Yoshida (ORCID: https://orcid.org/0000-0002-3834-0153)
- Arisa Wada
- Haruka Ito (ORCID: https://orcid.org/0000-0003-0652-6778)
- Hironori Fukuda (ORCID: https://orcid.org/0009-0008-3009-0146)
- Takashi Ikeda (ORCID: https://orcid.org/0000-0003-3976-5230)
- Takayuki Nakayama
- Ryo Minoda
- Maki Yoshino
- Junpei Iizuka
Institutions
- Tokyo Women's Medical University Hospital (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2025-09-01
- DOI
- https://doi.org/10.21873/cdp.10481
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01